Sinclair Pharma PLC Hardman Research: Demand growing in target markets
October 02 2017 - 2:15AM
RNS Non-Regulatory
TIDMSPH
Sinclair Pharma PLC
02 October 2017
Hardman Research: Demand growing in target markets
Demand growing in target markets - In 2016 Sinclair was
transformed into a streamlined, pure-play aesthetics company with a
concentrated, competitive portfolio of differentiated injectable
products. Effective, longer-lasting, natural looking, minimally
invasive treatments are benefiting from trends away from intensive
plastic surgery and represent a major growth opportunity. Strong
Silhouette sales in the US and Brazil, and declining Sculptra sales
are pushing gross margins >70%. Demand in Brazil, the US, and
China is set to deliver major value following approvals in the
near- and mid-term. In market US demand has lifted InstaLift sales
to $2.9m/GBP2.3m.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/02.10.17-demand-growing-in-target-markets.pdf
To contact us: Contacts:
Hardman & Co Dr Martin Hall
35 New Broad Street mh@hardmanandco.com
London Dr Dorothea Hill
EC2M 1NH dmh@hardmanandco.com
Dr Gregoire Pave
gp@hardmanabdco.com
Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEASNNALPXEFF
(END) Dow Jones Newswires
October 02, 2017 02:15 ET (06:15 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024